Simulations Plus, Inc. (SLP)

48,01 0,00 (0,00 %) À partir de 04:00PM EDT. Marché ouvert.

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
https://www.simulations-plus.com

Secteur(s): Healthcare
Secteur d’activité: Health Information Services
Employés à temps plein: 192

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Walter S. Woltosz M.A.S., M.S.	Co-Founder & Chairman	80k	S.O.	1945
Mr. Shawn M. O'Connor	Chief Executive Officer	847,56k	S.O.	1960
Mr. William Frederick	COO, CFO & Secretary	443,12k	1,29k	1964
Mr. John Anthony DiBella M.S.	President of PBPK & Cheminformatics Solutions	399,8k	2,13M	1980
Dr. Brett A. Howell Ph.D.	President of Quantitative Systems Pharmacology Solutions	321,67k	S.O.	1984
Ms. Jill Fiedler-Kelly M.S.	President of Clinical Pharmacology & Pharmacometrics Services	393,77k	17,43k	1969
Ms. Viera Lukacova Ph.D.	Chief Science Officer	S.O.	S.O.	S.O.
Dr. Bud Nelson J.D., Ph.D.	VP of Corporate Counsel & Personal Data Protection Officer	S.O.	S.O.	S.O.
Ms. Arlene Padron	Corporate Director of Marketing	S.O.	S.O.	S.O.
Dr. Scott Q. Siler	Chief Scientific Officer of DILIsym Services, Inc	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Simulations Plus, Inc. en date du 1 mai 2024 est 2. Les scores principaux sont Audit : 2; Société : 5; Droits des actionnaires : 1; Compensation : 5.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.